Business Context and Reporting Period
This Form 8-K is a current report filed by Immunocore Holdings plc on January 27, 2026. The filing addresses a specific corporate governance event regarding the departure of a senior executive.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is limited to personnel changes and does not contain financial statements or performance data.
Material Changes
The material change reported is the resignation of David Berman as Head of Research & Development, effective February 27, 2026. Dr. Berman is leaving to pursue another opportunity. The Company explicitly states that the resignation was not the result of any disagreement regarding operations, policies, or practices.
Outlook and Management Commentary
Management has indicated that the Company will not seek a direct replacement for Dr. Berman. Instead, the organization plans to streamline and leverage its existing R&D structure to accommodate the departure.
Investor Verification Checklist
- Confirm the effective date of Dr. Berman's resignation (February 27, 2026).
- Verify the Company's strategy to restructure R&D without a direct replacement.
- Review subsequent filings for any impact on ongoing clinical trials or R&D pipelines.
- Check for any undisclosed disagreements or litigation related to the departure.